Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Pliva history
Pliva company history timeline
Since the 1980 year Lachema Brno was ranked among the leading pharmaceutical companies in Czechoslovakia.
PLIVA researchers patented a new fast-acting macrolide antibiotic dubbed Azithromycin in 1980.
United States-based Pfizer began licensing production of the drug for sale in Europe and the United States in 1986, where it became a bestseller under the name Zithromax.
PLIVA's longtime president and CEO Zeljko Covic left the company for two years beginning in 1991.
Revenues were $300 million in 1994, with more than 40 percent from exports.
Revenues were about $400 million in 1995.
Sales to Russia more than doubled in 1997.
The Croatian government sold off the last of its directly owned, 14 percent shareholding in 1998.
In 2000, worldwide azithromycin sales accounted for nearly a quarter, or HRK 854 million ($107 million), of PLIVA's total revenues.
Sobel Holdings, Inc., PLIVA's first United States purchase, was acquired in June 2002 for $212 million.
Designed by British architectural firm Sheppard Robson, it opened in 2002.
PLIVA adopted a new, streamlined organizational structure in January 2004.
Revenues rose 5 percent to $1.1 billion (HRK 6.8 billion) in 2004.
In 2006 Pliva became part of the United States generic pharmaceutical company Barr Pharmaceuticals.
Finally, in 2008, Barr was acquired by Teva and Lachema was subsequently shut down.
Rate how well Pliva lives up to its initial vision.
Pliva jobs
Do you work at Pliva?
Does Pliva communicate its history to new hires?
Pliva competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Catalent Pharma Solutions | 2007 | $4.4B | 14,000 | 330 |
| DPT Laboratories | 1938 | $320.0M | 510 | 7 |
| Impax Laboratories | 1993 | $775.8M | 1,257 | - |
| CorePharma | 1995 | $15.0M | 200 | - |
| Par Pharmaceutical Inc | 2003 | $260.0M | 400 | - |
| US Pharma Lab | 1996 | $202.0M | 150 | 367 |
| Caraco Pharmaceutical Laboratories | - | - | - | - |
| AGC Biologics | - | $9.8M | 2,151 | - |
| Renaissance Pharma | 2000 | $10.0M | 7 | 4 |
| Tris Pharma | 2000 | $102.0M | 200 | 13 |
Pliva history FAQs
Zippia gives an in-depth look into the details of Pliva, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Pliva. The employee data is based on information from people who have self-reported their past or current employments at Pliva. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Pliva. The data presented on this page does not represent the view of Pliva and its employees or that of Zippia.
Pliva may also be known as or be related to Pliva and Pliva Inc.